Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)
Phase 3
Completed
- Conditions
- Postmenopausal Osteoporosis
- Interventions
- Drug: Risedronate 35 mgDrug: AlendronateDietary Supplement: Elemental CalciumDietary Supplement: Vitamin DDrug: Alendronate placeboDrug: Risendronate placebo
- First Posted Date
- 2004-09-24
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 1053
- Registration Number
- NCT00092014
Study of MK0476 (Montelukast Sodium) and Effects on Asthma and Nasal Symptoms Upon Exposure to Cats (0476-256)
Phase 3
Completed
- Conditions
- Asthma, BronchialRhinitis, Allergic, Perennial
- First Posted Date
- 2004-09-24
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 58
- Registration Number
- NCT00092105
Study of Investigational Drug in Osteoporosis (MK-0217-908)
- First Posted Date
- 2004-09-24
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 203
- Registration Number
- NCT00092053
Study of Montelukast and Its Effect on Lower Leg Growth in Children With Asthma (MK-0476-254)
Phase 4
Completed
- Conditions
- Asthma, Bronchial
- Interventions
- Drug: Budesonide inhalerDrug: Montelukast chewable tabletsDrug: Placebo to montelukast chewable tabletsDrug: Placebo to budesonide inhaler
- First Posted Date
- 2004-09-24
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 71
- Registration Number
- NCT00092092
Effectiveness of Two Approved Drugs in Lowering High Cholesterol (0733-224)
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2004-09-24
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 571
- Registration Number
- NCT00092157
Study of an Approved Drug in Patients With Asthma (0476-289)(COMPLETED)
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2004-09-24
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 500
- Registration Number
- NCT00092144
A Study to Evaluate the Safety, Tolerability, and Efficacy of an Investigational Drug and Dietary Supplement in Men and Postmenopausal Women With Osteoporosis (0217A-227)
Phase 3
Completed
- Conditions
- OsteoporosisVitamin D Deficiency
- First Posted Date
- 2004-09-24
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 717
- Registration Number
- NCT00092066
A Study and 12 Month Extension to Evaluate Two Investigational Drugs in Postmenopausal Women With Osteoporosis (MK-0217-907)
Phase 3
Completed
- Conditions
- Osteoporosis, Postmenopausal
- First Posted Date
- 2004-09-24
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 936
- Registration Number
- NCT00092040
Montelukast in Exercise-Induced Bronchospasm - 2003 (0476-270)
Phase 3
Completed
- Conditions
- Asthma, Exercise-Induced
- First Posted Date
- 2004-09-24
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 51
- Registration Number
- NCT00092131
A Study to Evaluate the Safety and Tolerability of MK0217 in Women (0217-219)
Phase 3
Completed
- Conditions
- Postmenopausal Osteoporosis
- First Posted Date
- 2004-09-24
- Last Posted Date
- 2024-08-14
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 454
- Registration Number
- NCT00092027
© Copyright 2025. All Rights Reserved by MedPath